Our two lead programs are currently in proof-of-concept trials: VENT-03, a first-in-class cGAS inhibitor in Phase 2 for lupus, with significant expansion opportunities across I&I and cardiometabolic conditions; and VENT-02, a brain-penetrant NLRP3 inhibitor in Phase 2 for Parkinson’s disease. Our pipeline also includes VENT-04, a first-in-class caspase-4/5 inhibitor for IBD, severe asthma and HS.
Our robust pipeline of differentiated therapeutics aims to address biologically validated drug targets that have been previously considered undruggable or areas where current therapies are insufficient for patients.
Our pipeline is powered by ReSOLVE® – a powerful platform combining the latest advances in AI/ML, protein science, structural biology, and biophysics to substantially increase the speed and accuracy of small-molecule drug discovery.
